Small-molecule inhibitors, including AKR1B10 inhibitors (e.g., statil, epalrestatl) 43 and CYP1B1 inhibitors (e.g., flavonoids, trans-stilbenes) 44, have shown preclinical efficacy in suppressing tumor growth. Here, AKR1B10 is linked to neoplasm.